cancer clinical trials for Myeloma/Plasma Cell Dyscrasia (ONC)
10 Myeloma/Plasma Cell Dyscrasia (ONC) clinical trials found. View a list of all cancer clinical trial types.
-
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
Current Status: Open
View links and contact information related to this clinical trial -
A Phase 1 Multicenter, Open-Label Study to Determine the Recommended Dose and Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose For Each Add On Investigational Component
Current Status: Open
View links and contact information related to this clinical trial -
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis (AFFIRM-AL)
Current Status: Open
View links and contact information related to this clinical trial -
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecaptagene Vicleucel CAR-T in Multiple Myeloma Patients
Current Status: Open
View links and contact information related to this clinical trial -
Expanded Access Protocol (EAP) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming For Commercial Release
Current Status: Open
View links and contact information related to this clinical trial -
Post Trial Access of Modakafusp Alfa (TAK-573) monotherapy or in Combination for the Treatment of Advanced Multiple Myeloma
Current Status: Closed
View links and contact information related to this clinical trial -
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
Current Status: Open
View links and contact information related to this clinical trial -
Intermediate-Size Population Expanded Access Program (EAP) for cilta-cel Out-of-Specification (OOS) in Patients with Multiple Myeloma
Current Status: Open
View links and contact information related to this clinical trial -
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
Current Status: Open
View links and contact information related to this clinical trial -
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Current Status: Open
View links and contact information related to this clinical trial